Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
about
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicineEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Enhancing mTOR-targeted cancer therapy.Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancerMolecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.A deut of mTORC1/2 for cell adhesion.Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo.RSUME inhibits VHL and regulates its tumor suppressor function.
P2860
Q26779144-874FE8E5-7A4B-49D2-AE3B-FB808D217BDDQ30313117-FC691F4C-BC38-41BE-8F27-B53E75C4C12EQ33422258-5EF4975E-9F3C-48C4-8211-6FBEDF519000Q33604979-C0D37AF1-D0DC-4652-B204-3CA41AF7C2BCQ34002839-719D0473-051A-4937-BAAA-74CD1CACB4BDQ35740165-2DE7C0B3-8D96-4349-A840-4AF2F846FCB6Q37081930-398162CE-6E9A-41FE-9AD9-96316A948FBBQ38936109-E2301811-91D5-4B73-A63A-19BD79F530FAQ39038881-55AF4D3B-72C4-4797-8C3B-CF67B4E12A67Q39642981-74AF751C-C458-49A3-BAAC-FB2086A19156Q42159286-5676DB05-4751-4EBA-8D37-56DC4DDA65B4Q50682953-C9BD5E1D-A39A-4A07-AB6B-F1F6FAE42347Q53670511-49DA251B-578C-4309-86BB-108B31956EE2
P2860
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@ast
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en-gb
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@nl
type
label
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@ast
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en-gb
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@nl
prefLabel
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@ast
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en-gb
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@nl
P2093
P2860
P356
P1433
P1476
Combining the receptor tyrosin ...... of renal cell carcinoma cells
@en
P2093
Ausra Mickuckyte
Dietger Jonas
Eva Juengel
Iyad Natsheh
Johanna Engler
Lukasz Hudak
Roman A Blaheta
P2860
P2888
P356
10.1186/1471-2407-9-161
P407
P577
2009-01-01T00:00:00Z
P5875
P6179
1017485574